Amundi
VKTX icon

Amundi’s Viking Therapeutics VKTX Stock Holding History

Amundi’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-6,443
Closed -$210K – 2178
2026
Q1 		$210K Buy
+6,443
New +$207K ﹤0.01% 1867
2025
Q2 		– Sell
-3,043
Closed -$73.7K – 2168
2025
Q1 		$73.7K Buy
3,043
+27
+0.9% +$853 ﹤0.01% 1781
2024
Q4 		$122K Sell
3,016
-30,538
-91% -$1.74M ﹤0.01% 1771
2024
Q3 		$2.24M Buy
+33,554
New +$1.97M ﹤0.01% 1130

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Amundi's VKTX Position: Q2 2026 in Review

Amundi sold out of Viking Therapeutics (VKTX) in Q2 2026, closing a stake of 6,443 shares — an estimated $210K sold.

Amundi first reported a position in VKTX in Q3 2024 and held it in 4 quarters. The position peaked at $2.24M in Q3 2024. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Amundi reported no remaining Viking Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Amundi sold 6,443 Viking Therapeutics shares in Q2 2026, an estimated $210K.
  • Amundi first reported a position in Viking Therapeutics in Q3 2024 and held it in 4 quarters.
  • Amundi's Viking Therapeutics position peaked at $2.24M in Q3 2024.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Amundi's 13F filing for Q2 2026, filed 11 Aug 2026.